PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Status: Recruiting
DFCI Protocol ID: 15-369

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Conducting Institutions:

Dana-Farber Cancer Institute

Overall PI:

Daphne Haas-Kogan, Dana Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Lisa Doherty,

Eligibility Criteria

Inclusion Criteria:

--Patients must have radiographic progressive or recurrent confirmed WHO grade I or II

astrocytomas, that was confirmed histologically at initial diagnosis. Progressive or

recurrent disease should be based on MRI according to the definition below.

Eligible histologies:

  -  Pilocytic Astrocytoma - 90600112

  -  Astrocytoma, Low Grade (Fibrillary astrocytoma, WHO Grade 2) - 10065886

  -  Astrocytoma, Low Grade (Low-grade Astrocytoma, NOS, WHO Grade 2) - 10003571

       -  Tissue from the initial diagnosis or recurrence must be made available for

  correlative testing.

       -  Patients must have measurable disease, defined as at least one lesion that can

  be accurately measured in at least two dimensions on MRI.

       -  Patients may have had treatment (chemotherapy and/or radiotherapy) for any

  number of relapses prior to this recurrence.

       -  Patients must have received their last dose of myelosuppressive anticancer

  chemotherapy at least three (3) weeks prior to study registration or at least

  six (6)weeks of nitrosourea.

       -  Patients must have received their last dose of other investigational or

  biological agent > 7 days prior to study entry.

For agents that have known adverse events occurring beyond 7 days after administration,

this period should be extended beyond the time during which adverse events are known to

occur. This should be discussed with the study chair.

  -  If patients received prior monoclonal antibody treatment, at least three half-lives

     must be elapsed by the time of treatment initiation. These patients should also be

     discussed with the study chair.

  -  Patients must have received their last fraction of craniospinal or focal radiation to

     primary tumor or other sites >12 weeks (3 months) prior to registration.

     --Age ̢�ۡ��3 and ̢�ۡ�_21 years.

  -  Because no dosing or adverse event data are currently available on the use of

     everolimus in patients "3 years of age, these young children are excluded from this


       -  Life expectancy of greater than 8 weeks.

       -  Patients must be able to swallow pills.

       -  Patient must have a Karnofsky (if ̢�ۡ�� 16 years of age) or Lansky Performance score

  (if ̢�ۡ�_ 16 years of age) of ̢�ۡ��50 by the time of registration.

       -  Patients must have adequate bone marrow function (ANC ̢�ۡ�� 1,000/mm3, platelet

  count of ̢�ۡ�� 100,000/mm3, and hemoglobin ̢�ۡ�� 9 gm/dL) before starting therapy.

  Eligibility level for hemoglobin may be reached by transfusion.

       -  INR ̢�ۡ�_1.5. (Anticoagulation is allowed if target INR ̢�ۡ�_ 1.5 on a stable dose of

  warfarin or on a stable dose of LMW heparin for >2 weeks at time of


       -  Patients must have adequate liver function (SGPT/ALT ̢�ۡ�_ 2.5 times ULN and

  bilirubin ̢�ۡ�_ 1.5 times ULN) before starting therapy.

       -  Patients must have adequate renal function (serum creatinine ̢�ۡ�_ 1.5 times

  institutional ULN for age or GFR ̢�ۡ�� 70 ml/min/1.73 m2) before starting therapy.

       -  Patients must have cholesterol level "350 mg/dL and triglycerides " 400 mg/dL

  before starting therapy. In case one or both of these are exceeded, the patient

  can only be included after initiation of appropriate lipid lowering medication

  and documentation of cholesterol " 350mg/dL and triglycerides " 400mg/dl before

  start of therapy.

       -  Patients must have normal pulmonary function testing for age based on pulse


       -  The effects of everolimus on the developing human fetus at the recommended

  therapeutic dose are unknown. For this reason and because everolimus are known

  to be teratogenic, women of child-bearing potential and men must agree to use

  adequate contraception (hormonal or barrier method of birth control; abstinence)

  prior to study entry and for the duration of study participation. Should a woman

  become pregnant or suspect she is pregnant while participating in this study,

  she should inform her treating physician immediately.

       -  Female patients of child bearing potential must not be breastfeeding or pregnant

  as evidenced by a negative pregnancy test.

Exclusion Criteria:

  -  Patients receiving concomitant medication that may interfere with study outcome. For

     example, patients cannot be on enzyme inducing anticonvulsants like phenytoin.

  -  Patients should not receive immunization with attenuated live vaccines within one

     week of study entry or during study period. Close contact with those who have

     received attenuated live vaccines should be avoided during treatment with everolimus.

     Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral

     polio, BCG, yellow fever, varicella and TY21a typhoid vaccines

  -  Hepatitis B/C blood test must be done at screening for all patients. Patients who

     test positive for Hepatitis C antibodies and the Hepatitis B antigen are ineligible.

  -  A known history of HIV seropositivity. HIV-positive patients on combination

     antiretroviral therapy are ineligible because of the potential for pharmacokinetic

     interactions with everolimus. In addition, these patients are at increased risk of

     lethal infections when treated with marrow-suppressive therapy.

  -  Patients receiving chronic, systemic treatment with corticosteroids or another

     immunosuppressive agent. Topical or inhaled corticosteroids are allowed.

  -  Patients may not have therapy for this recurrence (including radiation).

  -  Patients who do not have measurable disease on MRI.

  -  Patients who have been previously treated with an mTOR inhibitor.

  -  Patients with a known hypersensitivity to everolimus or other rapamycins (e.g.

     sirolimus, temsirolimus).

  -  Patients receiving any other concurrent anticancer or investigational therapy.

  -  Patients with any clinically significant unrelated systemic illness that would

     compromise the patient's ability to tolerate protocol therapy.

  -  Impairment of gastrointestinal function or gastrointestinal disease that may

     significantly alter the absorption of everolimus (e.g., ulcerative disease,

     uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel


  -  Patients with inability to return for follow-up visits to assess toxicity to therapy.

  -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active

     infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac

     arrhythmia, or psychiatric illness/social situations that would limit compliance with

     study requirements.

  -  Patients with a history of any other cancer (except non-melanoma skin cancer or

     carcinoma in situ of the cervix), unless in complete remission and off of all therapy

     for that disease for a minimum of 3 years.

Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done

at screening for all patients. HBV DNA and HCV RNA PCR testing are required at screening

for all patients with a positive medical history based on risk factors and/or confirmation

of prior HBV/HCV infection.

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.